Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
by
, , , , and
Clara Esnault
1,2
,
David Schrama
2,
Roland Houben
2,
Serge Guyétant
1,3,
Audrey Desgranges
4,
Camille Martin
4,
Patricia Berthon
1,
Marie-Claude Viaud-Massuard
4,5,
Antoine Touzé
1, 
Thibault Kervarrec
1,3 and
Mahtab Samimi
1,6,* 1
Team “Biologie des Infections à Polyomavirus”, UMR INRAE ISP 1282, Université de Tours, 31 Avenue Monge, 37200 Tours, France
2
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
3
Department of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170 Chambray-les-Tours, France
4
McSAF, 1 rue Claude Thion, 37200 Tours, France
5
Team Innovation Moléculaire et Thérapeutique (IMT), Groupe Innovation et Ciblage Cellulaire (GICC) EA7501, Université de Tours, 31 Avenue Monge, 37200 Tours, France
6
Department of Dermatology, Université de Tours, CHU de Tours, Avenue de la République, 37170 Chambray-les-Tours, France
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(3), 778; https://doi.org/10.3390/cancers14030778
Submission received: 4 January 2022
/
Revised: 28 January 2022
/
Accepted: 1 February 2022
/
Published: 2 February 2022
(This article belongs to the Special Issue Rare Skin Cancers: Recent Advances in Classification and Management)
Simple Summary
Currently, the therapeutic arsenal to fight cancers is extensive. Among these, antibody–drug conjugates (ADCs) consist in an antibody linked to a cytotoxic agent, allowing a specific delivery to tumor cells. ADCs are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
Abstract
Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
